[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 959,511,680
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.48
  • Price/Sales 14.76
  • Price/Cash Flow 40.63
  • Price/Book 30.83

Options Overview Details

View History
  • Implied Volatility 32.57% (-1.60%)
  • Historical Volatility 40.02%
  • IV Percentile 23%
  • IV Rank 27.39%
  • IV High 47.67% on 07/30/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 8) 33.87 (3.25%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 54,511
  • Volume Avg (30-Day) 44,689
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 347,902
  • Open Int (30-Day) 333,691
  • Expected Range 1,007.78 to 1,075.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.78
  • Number of Estimates 6
  • High Estimate $9.26
  • Low Estimate $7.83
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +39.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
850.51 +22.47%
on 04/29/26
1,047.30 -0.54%
on 05/21/26
+138.63 (+15.35%)
since 04/21/26
3-Month
850.51 +22.47%
on 04/29/26
1,064.45 -2.14%
on 02/23/26
+32.13 (+3.18%)
since 02/20/26
52-Week
623.78 +66.99%
on 08/08/25
1,133.95 -8.14%
on 01/08/26
+316.70 (+43.69%)
since 05/21/25

Most Recent Stories

More News
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program

LLY : 1,041.65 (+2.24%)
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

MMA : 0.4900 (-3.73%)
BPC.CN : 0.4550 (+2.25%)
PNGAF : 0.3225 (-1.68%)
NVO : 44.39 (-1.51%)
HIMS : 24.01 (+4.21%)
LLY : 1,041.65 (+2.24%)
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness,...

MMA : 0.4900 (-3.73%)
BPC.CN : 0.4550 (+2.25%)
PNGAF : 0.3225 (-1.68%)
NVO : 44.39 (-1.51%)
HIMS : 24.01 (+4.21%)
LLY : 1,041.65 (+2.24%)
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

  In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥ 30% weight loss, a level long associated with bariatric...

LLY : 1,041.65 (+2.24%)
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

NVO : 44.39 (-1.51%)
LLY : 1,041.65 (+2.24%)
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference

INDIANAPOLIS , May 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's 42 nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky,...

LLY : 1,041.65 (+2.24%)
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth

Lilly to provide park and court to the City of Indianapolis as part of its 150th anniversary celebration

LLY : 1,041.65 (+2.24%)
This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

VKTX : 30.68 (+4.21%)
NVO : 44.39 (-1.51%)
LLY : 1,041.65 (+2.24%)
Lilly and UNICEF collaborate to give millions of children a healthier start

Six-year initiative to improve non-communicable disease prevention and care for children in low- and middle-income countries

LLY : 1,041.65 (+2.24%)
3 Dividend ETFs With 3 Different Income Flavors

Stock gains aren’t the only way to get ahead in the market. These dividend ETFs allow you to earn varying levels of passive income.

AVGO : 414.57 (-0.76%)
CVX : 191.01 (-0.17%)
VZ : 48.27 (+0.94%)
VIG : 231.05 (+0.15%)
XOM : 155.29 (-0.63%)
LLY : 1,041.65 (+2.24%)
SDIV : 25.47 (-0.20%)
SCHD : 32.25 (+0.40%)
TXN : 298.39 (-2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,077.26
2nd Resistance Point 1,062.28
1st Resistance Point 1,051.96
Last Price 1,041.65
1st Support Level 1,026.67
2nd Support Level 1,011.69
3rd Support Level 1,001.37

See More

52-Week High 1,133.95
Last Price 1,041.65
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.